AdaptHealth Corp.

Valuation Analysis

About the Company

AdaptHealth Corp., together with its subsidiaries, distributes home medical equipment (HME), medical supplies, and home and related services in the United States. It operates through Sleep Health, Respiratory Health, Diabetes Health, and Wellness at Home segments. The company offers sleep therapy equipment, supplies, and related services, such as continuous positive airway pressure and BiLevel services to individuals suffering from obstructive sleep apnea; oxygen and home mechanical ventilation equipment and supplies and related chronic therapy services; and medical devices, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; and other HME devices and supplies. It also provides PAP machines,

AdaptHealth Corp. Stock at a Glance

AdaptHealth Corp. (AHCO) is currently trading at $10.16 with a market capitalization of $1.4B. The 52-week range spans from $8.06 to $13.43; the current price is 24.3% below the yearly high. Year-over-year revenue growth stands at +5.4%.

💰 Dividend

AdaptHealth Corp. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

8 analysts rate AdaptHealth Corp. (AHCO) on consensus: Buy. The average price target is $14.00, implying +37.8% from the current price. Analyst price targets range from $11.00 to $18.00.

AdaptHealth Corp.: The Investment Case in Detail

AdaptHealth Corp. (AHCO) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Wall Street consensus sits at Buy with an average price target implying roughly 37.8% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Valuation in Context

The EV/EBITDA multiple of 5.69x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

What to Watch Next

• The analyst consensus price target implies 37.8% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to market-like volatility, elevated short interest (7.32%), higher leverage relative to equity.

Trading Data

Related Stocks in the Same Sector

Where can I buy AdaptHealth Corp.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.